Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) or HEARTLIGHT for the Treatment of Symptomatic Atrial Fibrillation
The purpose of this study is to demonstrate the safety and effectiveness of the CardioFocus Endoscopic Ablation System with Adaptive Contact (HeartLight) in the treatment of atrial fibrillation by creating electrical isolation of the pulmonary veins.
Stanford is now accepting new patients for this trial.
- device : EAS-AC (HeartLight)
- procedure : Control Arm Ablation
Phase: Phase 3
Ages Eligible For Study:
- 18 to 75 years. - paroxysmal atrial fibrillation - failure of at least one AAD - others